Events

April 25

The Future of Clinical Proteomics: New and Emerging Innovations in Next Generation Proteomics

Organizer: The seminar is organized by the Meilahti Clinical Proteomics Unit and the National Proteomics Consortium hosted by Biocenter Finland (BF).

 

Target group: The seminar is targeted to scientists, clinicians, graduate and post-graduate students, and other personnel. Students need to register to get credits for their presence.

 

Aim of the seminar:

It has become obvious in the recent years that new technologies are needed for several special and basic proteomics applications to overcome the limitations of the mass spectrometry-based classical proteomics technologies. Since the first publication of the partial human genome in 2000/2001, proteomics has desperately tried to answer the next big challenge and Biotech’s next mantra to reveal the human proteome, without great success. Large clinical cohorts have rarely been studied on the protein level in deep detail by any available mass spectrometry-based technology. MS instruments are slow and do not have the capability to be run in parallel for hundreds of samples simultaneously. Moreover, the high dynamic range of proteins in samples usually stored in any biobank (blood, CSF and other body fluids) give a MS instrument hard time to succeed. Therefore, several new technologies have arisen and are continuously developed to set a completely new level on modern clinical proteomics. Such technologies are often usable to biobank samples directly and they also show the capacity for high-throughput and speed, making them suitable for large scale patient sample cohorts. Another challenge for MS based proteomics is the determination of stoichiometries between different proteins or post-translational modifications of a protein. Alternative peptide sequencing technologies, such as fluorosequencing, are being developed to address these needs. At the same time, mass spectrometry field is far from stagnant. The instruments are becoming faster and more sensitive, and new sample preparation techniques address some of the shortcomings of MS-based analysis. The aim of this seminar is to give the listeners a glimpse of such new technologies and to provide a good summary and comparison on the use of the two top MS instruments of today (Thermo Fisher Scientific and Bruker Corporation) for clinical sample analyses.

Registration: by 23.4.24 https://elomake.helsinki.fi/lomakkeet/129499/lomakkeet.html


Program:

 

09:00 – 09:10 Introduction and Welcome, Marc Baumann, Director, Meilahti Clinical Proteomics Core Facility, University of Helsinki

 

09:10 – 09:50 “Deep, unbiased proteomics at scale” Dr. Markus Vossmann, Vice President & General Manager EMEA and APAC, SEER, Inc.

 

09:55 – 10:35 “Enhance proteomics with next generation protein sequencing technology from Quantum-Si”, Richard Broadhead, Senior Field Application Scientist, Quantum-Si

 

10:35 – 11:00 Coffee break

 

11:00 – 11:40 "Shaping the Future of Healthcare: The Impact of High-Throughput Proteomics", Dr. Huthayfa Mujahed, Field Application Scientist, Olink Proteomics

 

11:45 – 12:30 “From Early Discovery to Clinical Trials - advancing each stage with high-plex SomaScan® proteomics”, Dr. Gary Prescott, Field Applications Scientist, Somalogic

 

12:30 – 13:30 Lunch

 

13:30 – 14:10 Proteomics at the Crossroads: Balancing Throughput and Depth for Biomarker Discovery”, Dr. Julia Kraegenbring, Senior Application Scientist, Thermo Fisher Scientific

 

14:15 – 14:55 “MALDI Imaging of intact protein + Multiomics analysis from a single glass slide”, Dr. Michele Genangeli, Commercial Manager, Bruker (Remote)

 

15:00 – 15:30 Coffee break

 

15:30 – 16:10 "Robust and scalable single-molecule protein sequencing with fluorosequencing", Dr. Jagannath Swaminathan, Chief Technology Officer, Erisyon (Remote) 

 

16:15 – 16:55 “Expanding Proteomic Horizons with Single-Molecule Proteome and Proteoform Analysis”, Parag Mallick, Founder & Chief Scientist, Nautilus Biotechnology. (Remote) 

 

17:00 Closing remarks, Marc Baumann, Director, Meilahti Clinical Proteomics Core Facility, University of Helsinki



Start time: 25/04/2024 09:00
End time: 25/04/2024 17:00
Duration: 8 hours
Location: Biomedicum 1, seminar room 1-2
Type: Seminar
Organization: Clinical Proteomics Unit
Contact person: bmh-proteomics@helsinki.fi
April 25

Research to Business funding info session

Business Finland offers an excellent funding instrument designed to support the preparation for commercialisation of academic research results. This Research to Business funding is intended for projects within public research organisations, where research groups and researchers aim to commercialise their research results and develop their research into new businesses.

During the event you:

  • will get information about the key aspects of Research to Business funding,
  • learn how Helsinki Innovation Services Ltd coordinates and supports the application process of University of Helsinki applicants,
  • will get an idea of the timeline and different stages of a typical Research to Business project,
  • will learn about the benefits of commercialising research, from applying for Research to Business funding to setting up a company,
  • can ask questions.

 

The event is open to all researchers and staff from all scientific fields of the University of Helsinki.



Start time: 25/04/2024 10:00
End time: 25/04/2024 10:50
Duration: 50 minutes
Location: remotely
Type: Education
Organization: Business Finalnd
Contact person: harriet.haras@helsinki.fi
April 26

ONCOSYS Special seminar

Speaker: Simone Zaccaria

Tentative title: “Measuring the proliferation rates of single-cell tumour clones though cancer and metastatic evolution.”

Recent publications:

Myers et al. HATCHet2: clone- and haplotype-specific copy number inference from bulk tumor sequencing data. Preprint 2023.

Frankell et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature 2023.

Grigoriadis et al. CONIPHER: a computational framework for scalable phylogenetic reconstruction with error correction. Nature Protocols 2023.

Zaccaria & Raphael. Accurate quantification of copy-number aberrations and whole-genome duplications in multi-sample tumor sequencing data. Nature Communications 2020.

Pich et al. The translational challenges of precision oncology. Cancer Cell 2022.



Start time: 26/04/2024 10:00
End time: 26/04/2024 11:00
Duration: 1 hour
Location: Biomedicum 1, seminar room 3
Type: Seminar
Organization: UH, Faculty of Medicine
Contact person: karen.ahlnas@helsinki.fi
April 26

Dissertation: Karoliina Kotaniemi

Karoliina Kotaniemi,  University of Helsinki, Faculty of Medicine, Doctoral Programme in Oral Sciences
Complications, associated risk factors, and stability of the outcome of orthognathic surgery, with special interest in use of patient-specific implants

Opponent: docent Olli Teronen, University of Tampere



Start time: 26/04/2024 12:00
End time: 26/04/2024 14:00
Duration: 2 hours
Location: Haartman Institute, lecture hall 1, Haartmaninkatu 3, 00290 Helsinki
Type: Dissertation
Organization: UH, Faculty of Medicine
Contact person: karoliina.kotaniemi@helsinki.fi
April 26

Dissertation: Sebastian Stenman

Sebastian Stenman,  University of Helsinki, Faculty of Medicine, Doctoral Program in Clinical Research, Institue for Molecular Medicine Finland - FIMM
The prognostic significance of tall cells and lymphocytes in papillary thyroid carcinoma – the use of deep learning algorithms

Opponent: Affiliated Professor Catarina Eloy, Porto University





Start time: 26/04/2024 12:00
End time: 26/04/2024 14:00
Duration: 2 hours
Location: HUS Siltasairaala, Haartmaninkatu 4, luentosali HEL
Type: Dissertation
Organization: UH, Faculty of Medicine
Contact person: sebastian.stenman@helsinki.fi